Form 4: AdaptHealth Director Josh Parnes Amends Stock Option Exercise Period
SEC Form 4 Filing
Josh Parnes, a director at AdaptHealth Corp., amended the exercise period of his employee stock options, extending the deadline to March 31, 2025.
Summary
- On October 24, 2024, Josh Parnes, a director of AdaptHealth Corp., filed a Form 4 with the SEC.
- The filing reports an amendment to his employee stock options, initially granted on December 19, 2019.
- The amendment extends the post-termination exercise period from November 29, 2024, to March 31, 2025.
- This extension resulted in the deemed cancellation of the original option and the grant of a replacement option for 833,334 shares.
- The exercise price remains at $11.50 per share.
- Parnes also granted Jonathan Bush and Shannone Raybon power of attorney to handle SEC filings related to AdaptHealth securities.
- The power of attorney was executed on April 16, 2024.
Sentiment
Score: 7
Explanation: The document is neutral to positive. It reflects a standard corporate action related to executive compensation, suggesting continued alignment of interests. There are no indications of negative performance or concerns.
Positives
- The extension of the option exercise period provides Parnes with more flexibility.
- The power of attorney simplifies the process of SEC filings.
Future Outlook
The document does not contain specific forward-looking statements regarding the company's future performance, but the option amendment suggests a continued alignment of the director's interests with the company's long-term success.
Industry Context
This filing is a routine disclosure related to executive compensation and stock options, common in publicly traded companies. It reflects the ongoing management of equity-based incentives to align executive interests with shareholder value.
Comparison to Industry Standards
- Stock option grants and amendments are standard practice in the healthcare industry to incentivize executives and align their interests with company performance.
- Companies like ResMed and Stryker also utilize stock options as part of their executive compensation packages.
- The vesting schedules and exercise periods are generally comparable to industry norms, with vesting occurring over several years and exercise periods extending beyond the grant date.
Stakeholder Impact
- The extension of the option exercise period could potentially benefit the director, Josh Parnes.
- Shareholders may view this as a positive sign of continued commitment from a key member of the board.
Key Dates
| Date | Description |
|---|---|
| 2019-12-19 | Original grant date of the employee stock options. |
| 2020-12-31 | First vesting date of the options. |
| 2021-12-31 | Second vesting date of the options. |
| 2022-12-31 | Third vesting date of the options. |
| 2024-04-16 | Date of execution of the Power of Attorney. |
| 2024-10-24 | Date of the option amendment and Form 4 filing. |
| 2024-10-28 | Date of signature on the Form 4 filing. |
| 2024-11-29 | Original expiration date of the options. |
| 2025-03-31 | New expiration date of the options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.